Bin Yao

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.6K citations · Full text

Medicine, Immunology, Oncology +17

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 565 citations

Medicine, Oncology, Breast Oncology +13

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2019 · 100 citations

Medicine, Oncology, Pharmacology +16

Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer

Robert G. Prosnitz, Bin Yao, Catherine L. Farrell et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 85 citations

Medicine, Hematology, Oncology +15

Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs

Xin Chen, Ruojun Wang, Xinshu Zhao et al. · Carcinogenesis · 2006 · 80 citations · Full text

Medicine, Cancer Biology, Oncology +15